Attached files
| file | filename |
|---|---|
| EX-99.3 - EXHIBIT 99.1 - TG THERAPEUTICS, INC. | v101617_ex993.htm |
| EX-99.2 - EXHIBIT 99.1 - TG THERAPEUTICS, INC. | v101617_ex992.htm |
| EX-99.1 - EXHIBIT 99.1 - TG THERAPEUTICS, INC. | v101617_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report
(Date of earliest event reported): October 16, 2017
TG Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File
Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th
Floor
New York, New York 10014
(Address of
Principal Executive Offices)
(212) 554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
|
Written communications pursuant to Rule 425
under the Securities Act.
|
|
☐
|
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act.
|
|
☐
|
|
Pre-commencement communications pursuant to Rule
14d-2b under the Exchange Act.
|
|
☐
|
|
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act.
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On
October 16, 2017, TG Therapeutics, Inc. issued the following press
releases: (i) a press release providing an update on an FDA meeting
for the GENUINE Phase 3 trial; (ii) a press release announcing the
completion of full enrollment in the UNITY-CLL Phase 3 trial; and
(iii) a press release recapping clinical data presentations at the
upcoming 7th Joint
ECTRIMS-ACTRIMS Meeting (collectively, the “Press
Releases”). Copies of the Press Releases are being filed as
Exhibits 99.1, 99.2 and 99.3 and incorporated in this Item by
reference.
Item 9.01 Financial Statements And
Exhibits.
(d)
Exhibits.
99.1 Press
Release, dated October 16, 2017.
99.2 Press
Release, dated October
16,
2017.
99.3 Press
Release, dated October 16,
2017.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
TG Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
Date:
October 17,
2017
|
|
|
|
By: /s/
Sean A.
Power
|
|
|
Sean A.
Power
|
|
|
Chief Financial
Officer
|
|
|
|
INDEX
TO EXHIBITS
|
|
|
|
|
Exhibit
|
|
|
|
Number
|
|
Description
|
|
|
|
|
|
|
Press Release,
dated October 16,
2017.
|
|
|
|
|
|
|
|
Press Release,
dated October 16,
2017.
|
|
|
|
|
|
|
|
Press Release,
dated October 16,
2017.
|